Printer Friendly

Identifying and Converting Co-Promotion Opportunities in the Pharmaceutical Industry.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c39089) has announced the addition of "Pharmaceutical Co-Promotion Management" to their offering.

This report was developed to research pharmaceutical co-promotions - and what makes them successful. Pharmaceutical Co-Promotion Management examines the inner workings of pharmaceutical co-promotions. From overall budgets and control to in the field strategies and tactics, this report details the inner workings of some of the industry's top companies' co-promotions.

Pharmaceutical Co-Promotion Management analyzes co-promotion practices from some of the industry's top companies to provide all the steps necessary to build stronger, more successful co-promotions. From identifying and winning potential deals to structuring oversight to establishing in the field communication links, the report provides co-promotion leaders the tools to improve their efforts. Spending, staffing, structure and strategies of top pharmaceutical companies' co-promotions offers purchasers benchmarks for excellence.

The report makes its case with metrics and techniques for managing co-promotions:

--Investment and Structure - Overall co-promotion investment levels along with staffing levels and make-up of oversight groups.

--In the Field Strategy and Tactics - Analysis of sales functions' roles in co-promotions. From co-promotion leadership to in the field communication links and conflict resolution.

--Identifying and Converting Co-Promotion Opportunities - Analysis of business development's efforts in finding and winning co-promotion deals - from staffing and investment to strategy.

Companies Profiled in this Report Include:

--Abbott Labs

--Amgen

--Bayer

--Bristol-Myers Squibb

--Eisai

--GlaxoSmithKline

--KOS Pharma

--Novartis

--Merck & Co.

--Merck KGaA

--Pfizer

--Sanofi-Aventis

--Teva Neuroscience

For more information visit http://www.researchandmarkets.com/reports/c39089
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 5, 2006
Words:248
Previous Article:Toshiba Lighting & Technology Develops Small-Sized Ceramic Metal Halide Lamp.
Next Article:Urinary Incontinence Therapeutics Market Expected To Be Worth Approximately $3.7 Billion By 2010.


Related Articles
QUARK SIGNS RESEARCH PACT WITH SHIONOGI.
ADVANSTAR BUYS LICENSING SHOW; ENTERS INTO PARINERHSIP W/REED EXHIBITION.
COR Therapeutics, Inc. Reports First Quarter 2001 Financial Results.
COR Therapeutics, Inc. Reports Profitable Third Quarter.
Open source not fully exploited in UK ... NCC. (IT News).
REMINDER/Eisai Expands Research Triangle Park Facility.
IDEC Pharmaceuticals Reports Fifth Consecutive Year of Profitability With Earnings Per Share Increasing to $0.85 Per Diluted Share and Revenue Growth...
IDEC Pharmaceuticals Reports First Quarter 2003 Results; Rituxan Sales Increase 32% Over First Quarter 2002 and Earnings Increase to $0.24 Per...
Experts to Share Methods for Measuring Promotion Effectiveness and Building Patient Loyalty at Pharmaceutical Marketing Congress.
ASTELLAS' SCREENING TRIGGERS MILESTONE PAYMENT TO METABOLEX.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters